文献速递艾滋病与性传播感染

传播性HIV-1耐药对两种核苷(酸)类逆转录酶抑制剂联合整合酶抑制剂或蛋白酶抑制剂一线抗逆转录病毒治疗疗效的影响

Impact of transmitted HIV-1 drug resistance on the efficacy of first-line antiretroviral therapy with two nucleos(t)ide reverse transcriptase inhibitors plus an integrase inhibitor or a protease inhibitor.
PubMed 文献 · J Antimicrob Chemother · 2018-01-01

基于意大利ARCA观察性数据库,纳入1365例HIV-1感染初治患者,比较含整合酶抑制剂(INSTI)或增效蛋白酶抑制剂(bPI)方案。INSTI组中传播性耐药且对至少一种处方药低水平耐药者48周病毒学失败累积估计为50%,显著高于无耐药者的6%。bPI组病毒学失败率不受基线耐药影响。

要点

  • INSTI组耐药分类C(对至少一种处方药低水平耐药)48周病毒学失败累积估计为50%,耐药分类A为6%。
  • bPI组48周病毒学失败累积估计为11%,INSTI组为7.7%。
  • 耐药分类C(对比A)调整后风险比aHR 12.6(95%CI 3.2-49.8,P<0.001),为病毒学失败预测因素。

核心结论

  • 数据支持在开始基于INSTI的一线ART时进行NRTI耐药基因型检测。

研究设计与样本

  • 意大利观察性数据库(ARCA)研究,纳入HIV-1感染初治患者1365例,开始两种NRTIs联合一种INSTI或bPI,且有治疗前耐药基因型。
  • 中位随访96周(IQR 54-110),bPI组1205例(88.3%),INSTI组160例(11.7%)。
  • 终点为病毒学失败(VF;第24周后血浆HIV-1 RNA>200 copies/mL)。
  • 采用WHO监测耐药突变和Stanford算法将患者分为三类:A无TDR,B有TDR但处方ART完全有活性,C有TDR且对一种或以上处方药至少低水平耐药。

主要发现

  • TDR患病率:NRTI 6.1%,NNRTI 12.5%,bPI 2.6%,INSTI 0%。
  • 48周VF累积Kaplan-Meier估计:bPI组11%(95%CI 10.1%-11.9%),INSTI组7.7%(95%CI 5.4%-10%)。
  • INSTI组48周VF累积估计:耐药分类A为6%(95%CI 4%-8%),B为5%(95%CI 1%-10%),C为50%(95%CI 30%-70%)(P<0.001)。
  • INSTI组中耐药分类C(对比A)aHR 12.6(95%CI 3.2-49.8,P<0.001),基线CD4每增加100 cells/mm3 aHR 0.6(95%CI 0.4-0.9,P=0.03),均预测VF。
  • bPI组VF率不受基线耐药影响。

临床怎么用

  • 原文结论支持在开始基于INSTI的一线ART时进行NRTI耐药基因型检测。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To examine the impact of transmitted drug resistance (TDR) on response to first-line regimens with integrase strand transfer inhibitors (INSTIs) or boosted protease inhibitors (bPIs). METHODS: From an Italian observational database (ARCA) we selected HIV-1-infected drug-naive patients starting two NRTIs and either an INSTI or a bPI, with an available pre-ART resistance genotype. The endpoint was virological failure (VF; plasma HIV-1 RNA >200 copies/mL after week 24). WHO surveillance drug resistance mutations and the Stanford algorithm were used to classify patients into three resistance categories: no TDR (A), TDR but fully-active ART prescribed (B), TDR and at least low-level resistance to one or more prescribed drug (C). RESULTS: We included 1365 patients with a median follow-up of 96 weeks (IQR 54-110): 1205 (88.3%) starting bPI and 160 (11.7%) INSTI. Prevalence of TDR was 6.1%, 12.5%, 2.6% and 0% for NRTI, NNRTI, bPI and INSTI, respectively. Cumulative Kaplan-Meier estimates for VF at 48 weeks were 11% (95% CI 10.1%-11.9%) for the bPI group and 7.7% (95% CI 5.4%-10%) for the INSTI group. In the INSTI group, cumulative estimates for VF at 48 weeks were 6% (95% CI 4%-8%) in resistance category A, 5% (95% CI 1%-10%) in B and 50% (95% CI 30%-70%) in C (P < 0.001). Resistance category C [versus A, adjusted hazard ratio (aHR) 12.6, 95% CI 3.2-49.8, P < 0.001] and nadir CD4 (+100 cells/mm3, aHR 0.6, 95% CI 0.4-0.9, P = 0.03) predicted VF. In the bPI group, VF rates were not influenced by baseline resistance. CONCLUSIONS: Our data support the need for NRTI resistance genotyping in patients starting an INSTI-based first-line ART.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Spertilli Raffaelli C, Rossetti B, Paglicci L, et al. Impact of transmitted HIV-1 drug resistance on the efficacy of first-line antiretroviral therapy with two nucleos(t)ide reverse transcriptase inhibitors plus an integrase inhibitor or a protease inhibitor. J Antimicrob Chemother. 2018. PMID: 29945251. doi:10.1093/jac/dky211

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。